Adult epilepsy market to reach $17.bn across 7MM by 2035
The adult epilepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) …
Post
-
-
Sanofi abandons eczema drug approval efforts in another blow to OX40 class
Sanofi has chosen not to file for approval or continue the development of its immunology therapy, amlitelimab, in atopic dermatitis …
-
BeOne to invest $300m in US manufacturing facility expansion
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus …
-
FDA grants fast track designation for Lundbeck’s Lu AH69593
Lundbeck has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational treatment, Lu AH69593, …
-
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro …
-
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) orphan drug designation for AFTX-201, a treatment in development …
-
Evogene and ELEO to develop new oral PCSK9 inhibitors
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein …
-
Crystalys banks $130m to progress gout drug, plan for commercial readiness
Crystalys Therapeutics has secured $130m in a Series B raise to push its gout therapy, dotinurad, further down the pipeline, …
-
Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing
Known for their low-dose therapeutic efficacy and high target affinity, HPAPIs are in high demand by biopharma companies, which often …
-
Samsung Biologics: geographic diversification is a sound business decision
South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics has been on a steep upward growth trajectory since receiving …
-
US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028
Following a period of immunity from US import tariffs, the global generics sector may now have to contend with similar …
-
Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita …
-
Cellares and Papillon partner for PPL-001 manufacturing automation
Cellares and Papillon Therapeutics have entered a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the …
-
Novo sues Lilly after alleged misleading and false advertising campaign
Novo Nordisk has filed a lawsuit against Eli Lilly, accusing its fellow obesity drug titan of peddling false advertising claiming …
-
Why Japan is a global destination for regenerative medicine
Through recent regulatory and policy reforms, Japan is becoming an increasingly attractive location for clinical research and development programmes, particularly …
